About ManagedLab

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium dolemue launti totam aperiam, eaque ipsa quae abillo. Invente veriatis et quasi.

Eying “Extra” DNA As Cancer Driver, Boundless Bio Debuts With $46M

Posted by |2019-09-19T02:00:27-07:00September 19th, 2019|

In the nucleus of human cells sit our chromosomes, comprised mainly of tightly wound DNA. In some cells, however, some pieces of genetic material that exist within the nucleus are not attached to a chromosome—and a new company, Boundless Bio, believes these “extra” pieces of DNA play a key role in driving some especially aggressive […]

Gilliland to Step Down as Head of Fred Hutch in 2020

Posted by |2019-09-17T16:18:23-07:00September 17th, 2019|

Gary Gilliland, who has led Seattle’s Fred Hutchinson Cancer Research Center as president and director for the past four-plus years, plans to step down in 2020, the nonprofit organization announced Tuesday. He joined the research center, which is often abbreviated as Fred Hutch, in 2015. Under his leadership, the organization has increased its endowment and […]

Lundbeck Paying Nearly $2B for Alder to Follow Migraine Rivals to Market

Posted by |2019-09-16T13:50:28-07:00September 16th, 2019|

Denmark’s neuroscience-focused pharma firm Lundbeck has agreed to pay $1.95 billion to acquire Seattle-based Alder BioPharmaceuticals to boost its late-stage pipeline and biologics capabilities. Barely a year at the helm, Lundbeck CEO Deborah Dunsire (pictured) is making her second major acquisition as she continues to look for new growth drivers to offset generics erosion of […]

Advisory Body Backs Aimmune Peanut Allergy Drug, Next Up: the FDA

Posted by |2019-09-16T03:30:07-07:00September 13th, 2019|

A panel of independent advisors to the FDA voted on Friday to recommend approval of an experimental peanut allergy drug from Aimmune Therapeutics. But concern about the risks of an allergic reaction to the therapy led the committee of mostly physicians to also recommend a safety plan to ensure that clinicians, patients, and their families […]

SpringWorks and Satsuma Boost This Week’s Biotech IPO Haul to $595M

Posted by |2019-09-12T18:15:57-07:00September 12th, 2019|

Wall Street welcomed three life science companies to the public markets this week. 10x Genomics led the way Wednesday, followed by SpringWorks Therapeutics and Satsuma Pharmaceuticals on Thursday. Combined, the three companies raised more than $595 million from their IPOs. According to IPO research firm Renaissance Capital, 153 IPOs have been filed to date in […]

FDA Doesn’t Shell Peanut Allergy Drug Pre-Hearing, Aimmune Shares Climb

Posted by |2019-09-11T12:42:42-07:00September 11th, 2019|

Peanut allergy sufferers know they need to stay away from certain foods that can put them in danger. But what about accidental exposure? Even trace amounts of peanut protein in their food or someone else’s can trigger an allergic reaction that sends them to the hospital. That’s what makes Palforzia, an experimental peanut allergy treatment […]

After First Look at House Drug Plan, Stocks Rise Slightly

Posted by |2019-09-10T13:28:56-07:00September 10th, 2019|

The first details of the long-awaited House Democrat plan to lower drug prices leaked out Monday night, with elements that have long been anathema to the biopharma industry and its supporters in Washington. While the world digested the details Tuesday, however, biopharma investors didn’t seem fazed. Some individual companies saw shares dip, but the biopharma […]

Acadia Stock Jumps on Positive Dementia-Related Psychosis Drug Data

Posted by |2019-09-09T14:08:38-07:00September 9th, 2019|

An Acadia Pharmaceuticals drug that’s already approved for psychosis associated with Parkinson’s disease could soon be heading to an FDA review to expand the use of the drug to dementia patients. On Monday, Acadia (NASDAQ: ACAD) reported that its drug, pimavanserin, met the goal of delaying relapse of psychosis in dementia patients compared to a […]

Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds

Posted by |2019-09-09T03:30:09-07:00September 6th, 2019|

Hearing loss affects millions of Americans but to date, there are no FDA-approved medicines to treat them. Frequency Therapeutics is developing a hearing loss drug that taps into the body’s regenerative capabilities. As the company prepares to advance the experimental treatment to mid-stage studies, it is planning an IPO to finance the research. Frequency set […]

Novartis & IFM Team Up Again, With Buyout Option for Autoimmune R&D

Posted by |2019-09-05T07:33:32-07:00September 5th, 2019|

IFM Therapeutics has lined up another pact with a big pharma company, and it’s the second one in less than a year with Novartis. Boston-based IFM Therapeutics announced Thursday that Novartis (NYSE: NVS) has agreed to pay the research and development costs of IFM Due, a subsidiary developing immunotherapies for inflammatory and autoimmune diseases. Novartis […]

Synlogic’s C-Suite Adds Richard Riese, CFO Todd Shegog to Depart

Posted by |2019-09-04T13:46:11-07:00September 4th, 2019|

Synlogic (NASDAQ: SYBX) has appointed Richard Riese to serve as chief medical officer. Riese was most recently vice president of clinical development at Alnylam Pharmaceuticals (NASDAQ: ALNY). In other moves, Synlogic announced that Todd Shegog, the company’s chief financial officer, will leave on Sept. 18 to pursue another opportunity. In a securities filing, Synlogic said […]

Vir Bio Plans IPO to Fund Clinical Trials of Infectious Disease Drugs

Posted by |2019-09-03T17:40:27-07:00September 3rd, 2019|

Vir Biotechnology assembled its pipeline of infectious disease compounds through deal-making with other drug developers, along with financial support from blue-chip venture capital firms and the non-profit Bill & Melinda Gates Foundation. Now the biotech is turning to the public markets for the cash to continue clinical tests of its most advanced drug candidates. San […]
Load More Posts